Select a medication above to begin.
Iyuzeh
latanoprost ophthalmic
Adult Dosing .
Dosage forms: SOL: 0.005%
elevated IOP
- [1 gtt in eye(s) qpm]
- Max: 1 dose/24h; Info: for pts w/ open-angle glaucoma or ocular HTN
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- hypersensitivity to benzalkonium chloride (preservative-containing form)
- herpes simplex keratitis, active
- intraocular inflammation, active
- caution: herpes simplex keratitis hx
- caution: intraocular inflammation hx
- caution: aphakia
- caution: pseudophakia w/ torn posterior lens capsule
- caution: macular edema risk
Drug Interactions .
Overview
latanoprost ophthalmic
prostaglandin F2-alpha analog
- alters intraocular pressure
Avoid/Use Alternative
- bimatoprost ophthalmic
- latanoprost ophthalmic
- latanoprostene bunod ophthalmic
- tafluprost ophthalmic
- travoprost ophthalmic
Adverse Reactions .
Serious Reactions
- macular edema
- herpes simplex keratitis reactivation
- superficial punctate keratitis
- uveitis
- iritis
- ocular pseudopemphigoid
- toxic epidermal necrolysis
- angina
Common Reactions
- foreign body sensation
- superficial punctate keratitis
- ocular stinging
- conjunctival hyperemia
- blurred vision
- ocular pruritus
- ocular burning
- iris hyperpigmentation
- lacrimation incr.
- eyelid discomfort
- eyelid pain
- dry eyes
- ocular pain
- eyelid crusting
- eyelid erythema
- URI
- photophobia
- eyelash growth
- eyelash darkening
- periorbital skin darkening
- nausea
- vomiting
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Look/Sound-Alike Drug Names
latanoprost confused with: bimatoprost; lansoprazole; Lantus; loteprednol
Pregnancy/Lactation .
Pregnancy
Clinical Summary
may use during pregnancy; risk of fetal harm not expected based on limited human data and minimal systemic absorption
Lactation
Clinical Summary
may use while breastfeeding; no human data available, though risk of infant harm and adverse effects on milk production not expected based on minimal systemic absorption in breastfeeding pts
Pharmacology .
Metabolism: local, liver; CYP450: unknown; Info: prodrug converted to latanoprost acid; minimal systemic absorption
Excretion: urine 88%; Half-life: 17min
Subclass: Glaucoma/Elevated IOP: Prostaglandin Agonists
Mechanism of Action
increases uveoscleral outflow, reducing IOP
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.